SCM
ACRS icon

Silverarc Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

Silverarc Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,400
Closed -$16.4K – 69
2023
Q3 		$16.4K Buy
+2,400
New +$20.5K 0.01% 80

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Silverarc Capital Management's ACRS Position: Q2 2026 in Review

Silverarc Capital Management opened a new position in Aclaris Therapeutics (ACRS) in Q2 2026: 1,946,482 shares worth $10.3M. The stake represents 1.07% of the portfolio and ranks #32 among its holdings. This is a return to the name: Silverarc Capital Management previously reported a position in ACRS as recently as Q2 2023.

Silverarc Capital Management first reported a position in ACRS in Q1 2021 and has held it in 11 quarters since. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Silverarc Capital Management held 1,946,482 shares of Aclaris Therapeutics worth $10.3M as of Q2 2026.
  • Aclaris Therapeutics was a new Silverarc Capital Management position in Q2 2026.
  • Aclaris Therapeutics made up 1.07% of Silverarc Capital Management's portfolio in Q2 2026, its #32 holding.
  • Silverarc Capital Management first reported a position in Aclaris Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.